CDH1 AND CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients

International Journal of Cancer

Volumn 109, Issue 2, 2004, Pages 163-166

  Widschwendter, Andreas ^a   Ivarsson, Lennart ^a   Blassnig, Anya ^a   Müller, Hannes M ^a   Fiegl, Heidi ^a   Wiedemair, Annemarie ^a   Müller Holzner, Elisabeth ^a   Goebel, Georg ^b   Marth, Christian ^a   Widschwendter, Martin ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Cervical cancer; E cadherin; H cadherin; Methylation; Relapse; Serum DNA

Indexed keywords

CADHERIN; DNA; GENE PRODUCT; H CADHERIN; H-CADHERIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BLOOD; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CDH1 GENE; CDH13 GENE; CELL ADHESION; CPG ISLAND; DNA METHYLATION; FEMALE; GENETICS; HUMAN; MAJOR CLINICAL STUDY; METABOLISM; METHYLATION; MORTALITY; ONCOGENE; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; SURVIVAL; SURVIVAL RATE; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 10744226762     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11706     Document Type: Article

References (24)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-78.
3. Graflund M, Sorbe B, Hussein A, Bryne M, Karlsson M. The prognostic value of histopathologic grading parameters and microvessel density in patients with early squamous cell carcinoma of the uterine cervix. Int J Gynecol Cancer 2002;12:32-41.
4. Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, Oikawa M, Yamamoto R, Yamada H, Fujimoto S. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 2002;81:1144-51.
5. Christofori G. Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J 2003;22:2318-23.
6. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26.
7. Carico E, Atlante M, Bucci B, Nofroni I, Vecchione A. E-cadherin and α-catenin expression during tumor progression of cervical carcinoma. Gynecol Oncol 2001;80:156-61.
8. Chen CL, Liu SS, Ip SM, Wong LC, Ng TY, Ngan HY. E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur J Cancer 2003;39:517-23.
9. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res 2001;61:4556-60.
10. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002;28:255-71.
11. Widschwendter A, Blassnig A, Wiedemair A, Muller-Holzner E, Muller HM, Marth C. Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Letters 2003;202:231-9.
12. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
13. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, Laird PW. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
14. Muller HM, Widschwendter M. Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn 2003;3:443-58.
15. Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Holzner E, Goebl G, Marth C, Widschwendter M. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 2003;in press.
16. Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001;7:1982-6.
17. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer 2003;2:24.
18. de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Wamaar SO, Fleuren GJ, Litvinov SV. Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. Am J Pathol 1999;155:505-15.
19. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000;36:1607-20.
20. Azarschab P, Stembalska A, Loncar MB, Pfister M, Sasiadek MM, Blin N. Epigenetic control of E-cadherin (CDH1) by CpG methylation in metastasizing laryngeal cancer. Oncol Rep 2003;10:501-3.
21. Franchi A, Gallo O, Boddi V, Santucci M. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination. Clin Cancer Res 1996;2:1801-8.
22. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, III, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.
23. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
24. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.